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 ABSTRACT 
 
The purpose of this study was to evaluate the performance of Neusilin®  (NEU) a synthetic 
magnesium aluminometasilicate as inorganic drug carrier co-processed with the hydrophilic 
surfactants Labrasol and Labrafil to develop Tranilast (TLT) based solid dispersions using 
continuous melt extrusion (HME) processing.  Twin ± screw extrusion was optimized to 
develop various TLT/excipient/surfactant formulations followed by continuous capsule filling 
in the absence of any downstream equipment. Physicochemical characterisation showed the 
existence of TLT in partially crystalline state in the porous network of inorganic NEU for all 
extruded formulations. Furthermore, in-line NIR studies revealed a possible intermolecular 
H±bonding formation between the drug and the carrier resulting in the increase of  TLT 
dissolution rates. The capsules containing TLT extruded solid dispersions showed enhanced 
dissolution rates and compared with the marketed Rizaben® product.  
 
Keywords: extrusion, solid dispersions, inorganic excipients, drug ± excipient interactions 
dissolution.  
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 1. Introduction 
The pharmaceutical industry is currently in the process of undergoing a transition from 
conventional batch manufacturing production to continuous processing. Due to market 
globalization, big pharmaceutical companies are facing immense challenges to comply with 
the demands of regulatory agencies, while the reduced lifespan of patents and overall 
decreased profitability of newly discovered drug substances are forcing them to shorten the 
drug development times with maximum throughput. Therefore, continuous manufacturing 
processes (CM) can be proved an efficient and promising alternative for achieving these 
goals [1]. CM provides better product quality assurance than batch processes, with less labor 
cost and development time. Furthermore, strong efforts are taken on the implementation of 
process analytical tools (PAT) for the purposes of in-line process monitoring and quality 
control [2-4].  
To date, hot melt extrusion (HME) has been utilised to a great extent for the development 
and optimisation of solid dispersions [5-14] in order to enhance the dissolution rate of water 
insoluble drugs [15-16]. Although HME is a versatile technology and can be used for 
continuous manufacturing of various pharmaceutical dosage forms, it has yet to be fully 
exploited for such purposes. Continuous HME offers several advantages such as small 
footprint, cost efficiency, reduced material waste and coupling with various PAT tools.   
The processing of inorganic excipients [17,18] as drug carries to increase dissolution rates 
of water insoluble drugs has recently gained interest for the development of solid dispersions. 
Bahl et al., evaluated the solubility and dissolution profiles of the poorly water-soluble drug 
indomethacin co-processed with Neusilin, an inorganic carrier, [19] using ball-milling 
micronization. The author found that the presence of silicic acid and Mg2+/Al3+ions, of NEU 
in the dissolution media increased the concentration of indomethacin and enhanced its in 
vitro dissolution rates. Maclean et al. (2011), described a robust extrusion process involving 
HME to form a Sulindac-NEU amorphous drug complex to enhance the dissolution rate of 
sulindac [20].   
Recently, Maniruzzaman et al., conducted extrusion studies to assess the performance of 
synthetic magnesium aluminometasilicate as an inorganic carrier for the development of 
stable indomethacin (IND) solid dispersions. Several IND/NEU blend ratios (20%, 30% and 
40%) were extruded continuously using a twin - screw extruder resulting in enhanced drug 
dissolution rates while the solid dispersions were stable for over 12 months [21]. The same 
group reported another study of an extrusion granulation process for the increased dissolution 
of the water insoluble ibuprofen (IBU). A quality-by-design (QbD) approach was 
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 implemented through a design of experiment to produce IBU loaded granules. The extruded 
granules showed significant enhancement in the dissolution profiles of ibuprofen, which were 
attributed to the intermolecular interactions of the drug and inorganic carrier [22].  
 Neusilin® (NEU) is considered a synthetic magnesium aluminometasilicate [23] that 
exhibits exceptional physical properties for improved drug delivery (e.g. high specific surface 
area, high flowability, amorphous). Tranilast (TLT) is classified as a BCS class II drug with 
solubility in water and acidic medium (pH 1.2) of 14.5 and 0.7 µg/mL, respectively [24,25]. 
Several studies have been reported on the development of TLT dosage forms including solid 
dispersions and nanoparticles [26-29] 
Up to date most of the research focuses on the HME processing of polymers, lipids or 
inorganic excipients as single drug carriers. Herein we present a two-fold study where 
inorganic excipients are co-processed with a variety of surfactants/solubilizers to produce 
stable solid lipid dispersions with enhanced drug dissolution rates. In addition, HME 
processing was optimized for continuous manufacturing of TLT capsules by direct feeding of 
the extruded formulations in a capsule-filling machine.  
 
2. Materials and method 
2.1 Materials 
Tranilast (TLT)   was purchased from Tokyo Chemical Industries (Japan) and 
Neusilin (NEU) was kindly donated by Fuji Chemical Industries Co., Ltd. (Japan). 
Labrasol (LSOL) and Labrafil (LFIL) were kindly donated by Gattefosse, 
France. All solvents used were of analytical grade and used as received. 
 
2.2 Solubility study of TLT in surfactants 
The phase solubility studies were performed to determine the solubility of TLT in the 
presence of various surfactants in a buffer solution (pH 6.8). An excess quantity of TLT was 
placed in 20 ml tube containing 10 ml of buffer medium with 1-5% surfactants (w/w). All test 
tubes were subjected to sonication for 20 min at room temperature followed by exposure to 
orbital shaking thermo stable incubator (Boekel Scientific, Germany) for 48 h at 37±0.5°C 
with rotating speed of 75 agitations /min. The supernatant solution was then passed through 
Whatman filter Paper (Grade 1) and analyzed by HPLC to quantify the amount of TLT 
dissolved. The best two surfactants were chosen to undertake further experiments.  
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2.3 Continuous hot-melt extrusion processing and manufacturing of capsules 
The prepared binary and ternary mixtures with either LSOL or LFIL as surfactants were 
extruded at temperatures varying from 170±200oC to find the suitable extrusion processing 
parameters (Table 1). The temperatures, screw speed and the torque forces were recorded for 
each processed sample. The screw speed used for extrusion was 50-100 rpm with a feed rate 
of 1 kg/hr. The EuroLab 16 (Thermo Fisher, Germany) is contacted to a terminal PC where 
the processing parameters are controlled through the appropriate software supplied by 
Thermo Fisher. The extrudates were collected in powder form and no additional downstream 
processing was required. Upon optimization of the extrusion process, the temperature of the 
final zones was set at 180 oC. 
     All extruded granules were fed to a Mini Cap capsule filler (Karnavati Engineering ltd, 
India) in line with the extruder in continuous manufacturing platform (Fig. 1). The machine 
output was set at 1500 capsules (0 size) per hour in automatic mode.  
 
2.4 Scanning electron microscopy (SEM) 
A cold-cathode field-emission gun scanning electron microscope (Hitachi SU8030 FEG-
SEM, Japan) was utilized to evaluate the extrudates spatial distribution of discreet chemical 
phases.  The samples were placed on double-sided carbon adhesive tabs and coated with 
carbon (Edwards 306 high vacuum carbon evaporation) before SEM analysis. The surface 
analysis to characterize the morphology of the pellets was evaluated using SEM at a nominal 
magnification of 1000 (area = 0.127 mm  0.095 mm). The accelerating voltage of the 
incident electron beam was set at 8 kV. This value was selected in order to minimize beam 
damage to the sample while maintaining adequate excitation. 
 
2.5 Particle size analysis 
The particle size distributions of the granules were determined using a Mastersizer 2000 
laser diffraction instrument (Malvern Instruments, UK) with a dry powder sample dispersion 
accessory (Scirocco 2000) and pressure at 0.5 bar and a vibration feed rate of 50%. Samples 
were run in triplicates. Mastersizer 2000 software was used for data evaluation.  
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 2.6 Thermal analysis 
A Mettler-Toledo 823e (Greifensee, Switzerland) differential scanning calorimeter 
(DSC) was used to carry out DSC runs of pure actives, physical mixtures and extrudates. 2-5 
mg of sample was placed in sealed aluminium pans with pierced lids.  The samples were 
heated at 10°C/min from 0°C to 220°C under dry nitrogen atmosphere and reheated at the 
same heating rate. 
Thermogravimetric analysis (TGA) measurements were conducted synchronously on a 
Q5000 (Thermal Analysis Company, USA). The vesicle samples were frozen in a liquid 
nitrogen bath followed by a vacuum freeze-drying step before TGA and DSC measurements. 
The lyophilized samples were placed into the alumina crucible with nitrogen as the reference. 
The heating-rate was 10oC/min from 25 to 250oC. 
 
2.7 X-ray powder diffraction (XRPD) 
XRPD was used to determine the solid state of pure active substances, physical 
mixtures and extruded materials using a Bruker D8 Advance (Germany) in theta-theta mode. 
For purposes of this study a Cu anode at 40kV and 40Ma, parallel beam Goebel mirror, 0.2 
mm exit slit, LynxEye Position Sensitive Detector with 3° opening (LynxIris at 6.5 mm) and 
sample rotation at 15 rpm were used. Each sample was scanned from 2 to 40° 2፽ with a step 
size of 0.02° 2፽ and a counting time of 0.1 seconds per step;  176 channels active on the PSD 
making a total counting time of 35.2 seconds per step. 
 
2.8 In-line Near Infra-Red (NIR) monitoring   
Near infrared spectrometry was performed during extrusion using an Antaris II NIR 
spectrometer (Thermo Scientific, UK) equipped with a halogen NIR source and InGaAs 
detector. The instrument utilised a fibre optic probe which was connected to the NIR 
spectrometer and used for in-line monitoring. NIR spectra were collected in real-time during 
the entire extrusion process via a fibre optic diffuse reflectance probe. All NIR in-line spectra 
were continuously collected using the RESULT Integration software (Version 3.0 Thermo 
Scientific, UK). Each spectrum was acquired by averaging 32 scans with a resolution of       
16 cmí1 over the 4,000±10,000 cmí1 wavenumber range. The acquisition of a full spectrum 
took approximately 16 s. The spectral pre-processing was performed using the TQ Analyst 
software (Version 8.6.12 Thermo Scientific, UK).  
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 2.9 In vitro dissolution study 
In vitro dissolution studies [30] were conducted in 900 ml of 0.2 M dihydrogen-sodium-
orthophosphate (pH adjusted with NaOH to 6.8) for 2 h using a Varian 705 DS dissolution 
paddle apparatus (Varian Inc. North Carolina, US) at 100 rpm. All formulations were directly 
dropped in the vessels without filling them in a capsule (n=3). Dissolution bath and vessels 
were equilibrated to 37 ± 0.5°C. Samples were withdrawn for HPLC assay at predetermined 
time intervals.  
 
2.9 HPLC analysis  
 The release of TLT was determined by using HPLC, Agilent Technologies system 1200 
series. A HYCHROME S50DS2-4889 (5 µm x 150 mm x 4mm) column was used for the 
HPLC analysis. The wavelength was set at 340 nm. The mobile phase consisted of 
methanol/water/triethyl amine (75/25/0.2 v/v) and the flow rate was maintained at 1.0 ml/min 
and the retention time was 2-3 min. Calibration curve was prepared with concentrations 
varying from 10 µg /ml to 50 µg/ml and 20 µl injection volumes. 
 
 
3. Results and discussion 
3.1 HME processing and capsule manufacturing 
In order to optimize the extrusion processing parameters, various TLT based 
formulations of different ratios and compositions were processed under different extrusion 
temperatures varying from 170-200oC. The solid-state analysis (see below) revealed that 
temperatures above 180oC are the most appropriate for the processing of TLT batches and the 
drug remained stable within the temperature range (melting point of TLT is above 200oC).  
Utilizing inorganic silicates as drug carriers during the HME process optimization resulted in 
the production of free flowing granules. NEU is considered an excellent excipient for 
extrusion purposes due to its higK IORZDELOLW\ &DUU¶V LQGH[ , high specific surface area 
and the drug absorbance within a silicate porous network [23].  
The TLT solubility studies conducted using a range of hydrophilic surfactants (suppl. 
material) revealed that both Labrafil and Labrasol have the highest solubilisation capacity for 
TLT in buffer solution (pH 6.8). Therefore, these two grades were used as hydrophilic 
surfactants and co-processed with NEU at high drug loadings (40-60% w/w ratios) as shown 
in Table 1. The extrusion of NEU in presence of liquid surfactants (10-15% w/w ratios) 
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 facilitated a complete dry blending resulting in the production of TLT loaded free flowing 
powders. 
The excellent flowability of the extruded powders was also achieved even at 60% drug 
loadings despite the poor flow properties of TLT and the surfactants used in the formulations. 
7KHHVWLPDWHG&DUU¶VLQGH[YDOXHVRI7/71(8DQG7/71(8surfactants extruded powders 
varied from 10-11, which are in the same range of the bulk inorganic NEU. The use of 
inorganic NEU and the process optimization in the absence of the extrusion die eliminated 
further downstream processing and provided high throughput of extruded formulations. 
Furthermore, HME was coupled successfully with a MiniCap auto capsule filler to 
manufacture capsules without the addition of other excipients. The process was allowed to 
operate continuously for 3hr and produced 1500 capsules µ¶VL]H) per hour.  
  
3.2 SEM and particle size analysis 
 SEM analysis was used to investigate the surface morphology of the bulk substances and 
the extruded formulations. As shown in Fig. 2a for all of the TLT/NEU formulations with or 
without surfactants no drug crystals can be identified on the NEU surface indicating excellent 
extrusion processing. Further observation shows that TLT/NEU extrudates formed 
agglomerates comprising of microstructured particles. The formation of agglomerates where 
the drug substance is adsorbed while the obtained particle size is similar to that of bulk NEU 
can be of great interest for the development of oral dosage forms (e.g. capsules) in a 
continuous manufacturing process without the requirement of further down-streaming 
processing. As shown in Fig. 2b the determined particle size distribution of all extruded 
batches and bulk NEU varied from 40 ± 300µm (d(0.9) = 300µm). Due to the drug/surfactant 
adsorption in the porous inorganic network further micronization was not required. 
 
3.3 Thermal analysis 
The bulk materials, physical mixtures and extruded formulations were further investigated 
by DSC analysis. As shown in Fig. 3a, pure TLT presented a sharp endotherm corresponding 
to its melting peak at 213oC ('H = 155.27 j/g). Synthetic 1(8GLGQ¶Wpresent any reversible 
thermal transition below 250oC in modulated DSC (MTDSC) (only a non-reversible thermal 
transition was seen at 165oC), which could be due to the loss of the two water molecules 
present in the NEU structure (Supp. Fig. 1).  
TLT/NEU (60/40 w/w) physical mixture (F3) showed a sharp endothermic thermal 
transition due to the melting of the drug at 213oC ('H = 174.51 J/g) (Fig. 3a). In contrast in 
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 the extruded formulation a slight shift of the TLT melting endotherm at 211.89oC ('H = 
160.01 J/g) was observed.  As shown in similar studies [31] of porous carriers the 
endothermic shift simply indicates the co-existence of amorphous and crystalline TLT in the 
porous network. A similar phenomenon was observed in TLT/NEU/LSOL extruded 
formulation (F5) with a significant shift of the melting endotherm towards lower 
temperatures at 202.37oC. In the physical blends of F5, TLT showed a melting peak at 
212.19oC, which was shifted at 201.33oC after the extrusion processing. In both cases the 
shift in the melting peak of TLT can be attributed to the presence of surfactant in the system. 
The liquid LSOL has partially solubilized TLT facilitating further adsorption in the inorganic 
carrier. It can also be seen that the melting peaks differ in shape where broader peaks suggest 
more drug melted within the pores. This indicates that the presence of hydrophilic surfactant 
such as LSOL may have played a key role in the solubilization of TLT during the extrusion 
process, which in turn is expected to show an impact in the in vitro dissolution rates. 
 
Thermo-gravimetric (TGA) analysis was performed to determine any potential material 
weight loss as a function of the increasing temperatures. As can be seen in Fig. 3b bulk TLT 
has not showed any weight loss up to 205oC while bulk NEU showed a net weight loss of 
about 12.0% at 200oC corresponding to the loss of two molecules. A similar thermal 
transition was observed in the MTDSC analysis as mentioned above. The bulk LSOL showed 
weight loss of 5.24% which is expected to not to provide any significant impact in the 
extruded formulations considering only 10% w/w ratio in the final formulation prior to the 
extrusion processing. Both the TLT/NEU and TLT/NEU/LSOL extruded formulations 
exhibited lower weight losses of 5.40% and 3.70% respectively. These weight losses are quite 
lower compared to bulk NUE suggesting that H2O molecules were not completely removed 
when NEU was co-processed with TLT or TLT/LSO. 
 
3.4 X-ray powder diffraction (XRPD) studies 
X±ray powder diffraction analysis of bulk substances and extruded granules, was 
performed in order to examine the physical state of the drug substance.  As can be seen in 
Fig. 4 and Supp. Fig. 2 the diffractogram of bulk TLT showed distinct intensity peaks due to 
its crystalline structure at 11.06o, 12.17o, 13.78o, 16.67o, 18.64o, 22.41o, 24.63o, 28.46o, 31.07o 
șGHJUHHV while NEU appeared  completely amorphous with no crystalline intensity peaks. 
The physical blends of all TLT formulations showed identical peaks without any reduction of 
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 the peak intensities due to the presence of crystalline TLT. Similarly, all extruded granules 
showed identical peaks at relatively low intensities suggesting a lower degree of crystalline 
TLT is present, alongside an increase of amorphous content during the extrusion processing, 
even at high 60% drug loading.  
 
 
3.5 In- line NIR spectroscopy monitoring  
Off-line NIR spectra of bulk TLT, excipients and physical blends were recorded in order to 
identify the characteristic bands of the bulk substances. An in-line NIR reflectance probe was 
coupled with HME processing to continuously monitor [32,33] all TLT based formulations. 
Furthermore, in-line NIR spectra of the TLT/NEU 60/40 (w/w) formulation was recorded 
during the extrusion at the third mixing zone. The second derivative spectra in Fig. 5a-d show 
a significant peak shift between the NIR spectra of bulk TLT and that in the extruded 
granules. The NIR signal of NEU was flat in the same region suggesting no effect on the drug 
absorption. In Fig. 5a it can be seen that the second derivative NIR spectra showed a 
significant peak shift, particularly in the range of 8800±8900 cm-1, indicating potential 
intermolecular interactions between the drug and the complex silicate. Interestingly, the 
dimer peaks of the bulk TLT at 8800 ± 8900 cm-1 disappeared in the extruded granules and 
showed a broad peak, which could be due to the TLT - NEU interactions but could also be 
attributed to the increase the amorphicity of the extruded materials.  
 
Furthermore, Fig. 5b shows that a peak at 7095 cm-1 attributed to the ±OH stretching first 
overtone of the drug TLT has been shifted to a new position at 7109 cm-1 in the TLT/NEU 
extrudates.  The peak shifting at this position is related to the H-bonding between the -COOH 
of TLT and the ±O group of NEU [34].  There are also two more peaks at 7385 cm-1 and 7212 
cm-1, which were shifted from 7402 cm-1 and 7234 cm-1 respectively. These two peaks are 
attributed to the ±CH stretching, and the reason of the peak shifting occurs is could be due to 
the formation of weak H-bond (C-H···O) between the drug and the excipient [35].  
Furthermore, another peak at 5206 cm-1 which is attributed to the C=O second overtone has 
also been shifted to 5230 cm-1 (Fig. 5c). This peak shifting is due to the formation of H-bond 
between the ±C=O of the drug and the excipient. The amide group (-CONH-R) of the drug 
was visible via an intense peak at 4668 cm-1, which has been slightly shifted and appears 
broader after the extrusion processing (Fig. 5d). This can be attributed to the increase in the 
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 amorphicity of the drug in the extruded formulations as confirmed by the XRD and DSC 
studies.  
 
3.6 In vitro dissolution studies 
In vitro dissolution studies of TLT formulations were compared with the bulk TLT and 
the commercial formulation (Rizaben®). The studies showed a significant improvement of 
the drug dissolution rates in phosphate buffer (pH 6.8). As shown in Fig. 6a, for the first 
60min TLT/NEU extruded (60% TLT loading w/w) formulation and Rizaben® presented 
similar dissolution rates (p>0.05), varying from 70±80%. However, after 120min the 
extruded formulation presented 100% TLT dissolution rates while Rizaben® reached a 
maximum of 81-84%. The increase of TLT loading in the extruded formulations resulted in 
faster dissolution rates for the first 60 min, as shown in Fig. 6a. It can also be seen that the 
dissolution rate of bulk TLT was approximately 40% after 120 min. No increase in the 
dissolution rates was observed for the physical mixtures (data not shown). An important 
observation is that TLT maintained a supersaturation state for 2h which allowed dissolution 
up to 100%.  In contrast Rizaben® capsules containing mainly HPMC reached an 84% drug 
dissolution after 2h. As primarily the improved dissolution rates are due to the presence of the 
selected excipients, the low Rizaben® dissolution is a result of the slow HPMC dissolution 
kinetics compared to NEU and NEU/solubilizer formulations [36,37].   
 
As shown in Fig. 6b for the co-processed NEU/LSOL extrudates the TLT dissolution rates 
were again similar to Rizaben® at 76% after 30 min but significantly higher after 60 min. 
The TLT/NEU/LFIL extrudate showed slower dissolution rates with around 61% for the first 
60 min compared to TLT/NEULSOL and Rizaben® respectively and 95% at 120 min. 
Interestingly, both formulations presented lower dissolution rates for the first 60 min in 
comparison to Rizaben®. The effect of the LSOL/LFIL solubilizers on the dissolution 
enhancement were evident after the first 30 ± 60 min. The dissolution rates of the physical 
mixtures (Fig. 6 suppl. material) showed a small increase due to the presence of surfactants 
and rates varied from 48 ± 52% after 2hr which, however was not a significant one. These 
results suggest a surfactant synergistic effect only when co-processed with inorganic NEU.  
 
The observed increase in the dissolution studies of TLT extruded formulations could be 
attributed to the effect of a) the sinalol groups in NEU, b) the presence of amorphous TLT 
due to the adsorption in the porous network and c) H-bonding interaction of TLT-NEU. As 
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 previously reported, NEU generates various silanol groups (e.g. free, germinal or associated) 
when in contact with water render it it a potential proton donor as well as a proton acceptor 
[22]. The existence of free silicic acid and ions (Mg2+ and Al3+) in the dissolution media may 
have played a vital role to cause the increase in the dissolution of TLT. The partially 
amorphous TLT adsorbed in the extruded formulations facilitates faster dissolution rates 
compared to the fully crystalline substance in the physical mixtures.  
 Furthermore, the increased TLT dissolution rates alongside the increased drug loadings in 
the extruded formulations resulted in stronger drug ± excipient interactions. Similar results 
were observed from Bahl et al. for indomethacin solid dispersions. In the present study, the 
increased dissolution rates in the presence of LSOL or LFIL within the extruded formulations 
is due to the solubilising capacity of the two surfactants.  However, as shown in Fig. 6b the 
presence of LSOL in the extrudates resulted in better dissolution rates compared to LFIL due 
to its better solubilizing effect on TLT as confirmed by the saturation solubility data (Supp. 
Fig. 3).  
As shown in Fig. 4 the granulated formulations presented amorphous TLT to some extent (5-
10%) which is expected to have an effect on dissolution rates. Indeed, sttability studies under 
accelerated condition (40oC/40% RH, data not shown) for six months presented a degree of 
TLT re-crystallization and changes on the dissolution rates. However, statistical analysis 
didn't reveal any significant changes on the dissolution rates (p>0.05) of the stability batches. 
This was attributed to the protective effect of NEU which promotes long term stability of the 
extruded granules. 
 
4. Conclusions 
 In the current study inorganic aluminocilicates were processed with or without 
surfactants and exploited as a suitable drug carrier for continuous extrusion processing to 
produce capsules with enhanced dissolution rates of the poorly water-soluble drug TLT. The 
process comprised of only 3 operational units for continuous extrusion processing followed 
by capsule filling in the absence of any downstream equipment. The process optimization 
resulted in 60% TLT loadings with excellent powder flowability of the extruded 
formulations. Physicochemical characterization showed drug adsorption in the porous 
inorganic network, while the presents of surfactants increase TLP dissolution rates. In vitro 
dissolution studies revealed a significant increase of the dissolution rates of extruded TLT 
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 formulations compared to that of marketed Rizaben£ capsules. Inorganic excipients were 
used as a paradigm for drug extrusion though continuous capsule filling.  
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 Table 1: Formulation composition of TLT based formulations 
Formulation TLT 
(w/w) 
NEU 
(w/w) 
LSOL 
(w/w) 
LFIL 
(w/w) 
1 40 60   
2 40 30   
3 60 40   
4 60 25 15  
5 60 25  15 
6 60 30 10  
7 60 30  10 
 
50/170/180/180/180/180/180/180/180oC (Feeder to die) 
Screw speed: 100 rpm, Feed rate: 1 kg/h 
 
 
 
Figures caption list 
 
Fig. 1 Schematic diagram of manufacturing TLT based capsule in a continuous 
process. 
Fig. 2a SEM images of (a-b) TLT/NEU 60/40 and (c-d) TLT/NEU/LSOL 60/30/10 
extruded formulations. 
Fig. 2b Particle size distribution of TLT extruded formulations comparing to the 
bulk NEU. 
Fig. 3a DSC thermal transitions of bulk TLT, TLT/NEU 60/40, TLT/NEU/LSOL 
60/30/10 and TLT/NEU/LFIL 60/30/10 formulations. 
Fig. 3b TGA thermograms of bulk TLT, NEU, TLT/NEU and TLT/NEU/LSOL 
extruded formulations. 
Fig. 4 XRD difffractograms of bulk TLT, NEU and TLT based physical mixtures 
(PM) and extruded formulations (EXT).  
Fig. 5  (a-d) 2nd derivative NIR spectra of TLT, NEU and TLT/NEU formulations. 
Fig. 6a In vitro TLT dissolution profiles of Rizaben and extruded formulation (n = 
3, pH 6.8). 
Fig. 6b In vitro TLT dissolution profiles of Rizaben and co-processed extruded 
formulations with NEU/LSOL (LFIL) (n=3, pH 6.8). 
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